Ginkgo Bioworks Reports Q3 Revenue of $27.711 Million
Q3 revenue fell 5.7% year over year to $27.711 million. Net loss narrowed to $40.984 million, or $0.64 per share, from $80.755 million, or $1.45 per share. The company reported its first autonomous lab platform sale and reaffirmed full-year cash-burn guidance of $125 million to $150 million.
Ginkgo Bioworks reported Q3 2026 revenue of $27.711 million, a 5.7% decrease from $29.380 million in the same period last year. The company's net loss narrowed to $40.984 million, or $0.64 per share, compared to a loss of $80.755 million, or $1.45 per share, in the prior-year period. A significant development for the quarter was the first sale of the company's autonomous lab platform. Management also reaffirmed its full-year cash-burn guidance of $125 million to $150 million, citing growing customer activity in its Cloud Lab offerings as a key driver for the business.